• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    New insider Walker Paul Edward claimed ownership of 1,072,936 shares (SEC Form 3)

    11/7/23 9:33:14 PM ET
    $FREQ
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $FREQ alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Walker Paul Edward

    (Last) (First) (Middle)
    1954 GREENSPRING DRIVE
    SUITE 600

    (Street)
    TIMONIUM MD 21093

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    11/03/2023
    3. Issuer Name and Ticker or Trading Symbol
    Korro Bio, Inc. [ KRRO ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Common Stock 1,072,936 I See Note 1(1)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. ("NEA Partners 17"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. ("NEA 17"), which is the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest.
    Remarks:
    /s/ Louis Citron, attorney-in-fact 11/07/2023
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $FREQ alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $FREQ

    DatePrice TargetRatingAnalyst
    2/15/2023Buy → Neutral
    Chardan Capital Markets
    2/13/2023Outperform → Market Perform
    Cowen
    9/22/2021$12.00 → $9.00Buy → Neutral
    Goldman Sachs
    More analyst ratings

    $FREQ
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Frequency Therapeutics downgraded by Chardan Capital Markets

      Chardan Capital Markets downgraded Frequency Therapeutics from Buy to Neutral

      2/15/23 10:23:29 AM ET
      $FREQ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Frequency Therapeutics downgraded by Cowen

      Cowen downgraded Frequency Therapeutics from Outperform to Market Perform

      2/13/23 11:23:43 AM ET
      $FREQ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Frequency Therapeutics downgraded by Goldman Sachs with a new price target

      Goldman Sachs downgraded Frequency Therapeutics from Buy to Neutral and set a new price target of $9.00 from $12.00 previously

      9/22/21 6:15:51 AM ET
      $FREQ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FREQ
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Frequency Therapeutics Inc. (Amendment)

      SC 13G/A - Korro Bio, Inc. (0001703647) (Subject)

      2/14/24 4:57:08 PM ET
      $FREQ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Frequency Therapeutics Inc. (Amendment)

      SC 13G/A - Korro Bio, Inc. (0001703647) (Subject)

      2/14/24 3:03:45 PM ET
      $FREQ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Frequency Therapeutics Inc.

      SC 13G - Korro Bio, Inc. (0001703647) (Subject)

      2/14/24 11:59:09 AM ET
      $FREQ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FREQ
    SEC Filings

    See more
    • SEC Form 424B3 filed by Frequency Therapeutics Inc.

      424B3 - Korro Bio, Inc. (0001703647) (Filer)

      1/9/24 9:02:50 AM ET
      $FREQ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Frequency Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Korro Bio, Inc. (0001703647) (Filer)

      1/9/24 9:00:59 AM ET
      $FREQ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Frequency Therapeutics Inc.

      EFFECT - Korro Bio, Inc. (0001703647) (Filer)

      12/26/23 12:15:11 AM ET
      $FREQ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FREQ
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $FREQ
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $FREQ
    Financials

    Live finance-specific insights

    See more
    • NorthStar Appoints Peter Pfreundschuh to Board of Managers

      NorthStar Medical Technologies, LLC, parent company of NorthStar Medical Radioisotopes, LLC, a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, today announced the appointment of Peter (Pete) Pfreundschuh to its Board of Managers, effective April 1, 2024. Following this appointment, the Board will comprise of 9 directors, 6 of whom are non-executive. "We are pleased to welcome Pete to the NorthStar Board," said Stephen Merrick, Executive Chairman of NorthStar. "Pete has deep experience in the pharmaceutical and biotechnology industry, with extensive knowledge in corporate finance, business

      4/15/24 9:00:00 AM ET
      $FREQ
      $URGN
      $VYGR
      $IMMU
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
    • Korro Bio and Frequency Therapeutics Announce Closing of Merger and Private Placement of $117 Million

      Korro will be focused on advancing a wholly owned portfolio of RNA editing programsPost-transaction cash of approximately $170 million expected to fund operations into 2026Funds multiple potentially value-creating milestones, including advancing its lead product candidate in Alpha-1 antitrypsin deficiency (AATD) through a clinical trialShares to trade on Nasdaq under the ticker "KRRO" commencing on November 6, 2023 CAMBRIDGE, Mass. and LEXINGTON, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO), a biopharmaceutical company with a mission to discover, develop and commercialize a new class of genetic medicines based on editing RNA, enabling treatment of both r

      11/3/23 12:19:45 PM ET
      $FREQ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Frequency Therapeutics Provides Business Updates and Second Quarter 2023 Financial Results

      Frequency Therapeutics, Inc. (NASDAQ:FREQ) today announced business updates and financial results for the second quarter ended June 30, 2023. In July, the Company announced that it entered into a definitive merger agreement with Korro Bio, Inc., a leading RNA editing company focused on the discovery and development of novel genetic medicines. After the anticipated consummation of the merger, the combined company will operate under Korro Bio, Inc. with a focus on the advancement of Korro Bio's portfolio of RNA editing programs and will trade on Nasdaq under the ticker symbol "KRRO." The merger is expected to close in the fourth quarter of 2023, subject to approval by Frequency Therapeutics

      8/10/23 4:01:00 PM ET
      $FREQ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Meyers Rachel

      4 - Korro Bio, Inc. (0001703647) (Issuer)

      11/29/23 4:55:57 PM ET
      $FREQ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Meyers Rachel

      3 - Korro Bio, Inc. (0001703647) (Issuer)

      11/29/23 4:53:41 PM ET
      $FREQ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lucchino David L. sold $43,573 worth of shares (1,156 units at $37.69), decreasing direct ownership by 5% to 22,150 units (SEC Form 4)

      4 - Korro Bio, Inc. (0001703647) (Issuer)

      11/27/23 8:48:47 PM ET
      $FREQ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Korro Bio and Frequency Therapeutics Announce Merger Agreement

      Merger to create a Nasdaq-listed genetic medicines company focused on advancing Korro Bio's wholly owned portfolio of RNA editing programs Lead program is a disease modifying therapy for patients with alpha-1 antitrypsin deficiency (AATD), with preclinical data showing an increase of normal A1AT protein to 85% of total protein in circulation  Combined company is expected to have cash balance of approximately $170 million at close, which is expected to provide cash runway through several value-creating milestones and into 2026 Companies to host conference call today at 8:30 a.m. ET Korro Bio, Inc., a leading RNA editing company focused on the discovery and development of novel geneti

      7/14/23 6:30:00 AM ET
      $FREQ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FREQ
    Leadership Updates

    Live Leadership Updates

    See more
    • NorthStar Appoints Peter Pfreundschuh to Board of Managers

      NorthStar Medical Technologies, LLC, parent company of NorthStar Medical Radioisotopes, LLC, a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, today announced the appointment of Peter (Pete) Pfreundschuh to its Board of Managers, effective April 1, 2024. Following this appointment, the Board will comprise of 9 directors, 6 of whom are non-executive. "We are pleased to welcome Pete to the NorthStar Board," said Stephen Merrick, Executive Chairman of NorthStar. "Pete has deep experience in the pharmaceutical and biotechnology industry, with extensive knowledge in corporate finance, business

      4/15/24 9:00:00 AM ET
      $FREQ
      $URGN
      $VYGR
      $IMMU
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
    • Frequency Therapeutics Expands its Clinical Development Team, Adding Expertise in Inner Ear Physiology and Translational Science

      Company Announces Appointment of Jeffery Lichtenhan, Ph.D., to Lead Efforts in Hearing Diagnostics and Measurement; Joins Frequency from Washington University Medical School in St. Louis Frequency Therapeutics, Inc. (NASDAQ:FREQ), a clinical-stage biotechnology company focused on harnessing the body's innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced the expansion of its clinical development team with the addition of Jeffery T. Lichtenhan, Ph.D., a leading expert in hearing diagnostics and measurement. Dr. Lichtenhan, an auditory neuroscientist, will help to advance the Company's hearing clinical development programs, including it

      4/13/21 7:00:00 AM ET
      $FREQ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Frequency Therapeutics Appoints Kevin Franck, Ph.D., as Senior Vice President, Strategic Marketing and New Product Planning

      WOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced the appointment of Kevin Franck, Ph.D., as Senior Vice President of Strategic Marketing and New Product Planning. Dr. Franck will lead pre-commercial strategy and launch planning for Frequency’s clinical pipeline, including its lead program aimed at developing a restorative treatment for sensorineural hearing loss (SNHL), the most common form of hearing loss. Dr. Franck is a leader in the hearing field with 25 years of experienc

      2/8/21 7:00:00 AM ET
      $FREQ
      Biotechnology: Pharmaceutical Preparations
      Health Care